Showing 501 - 520 results of 2,534 for search '"Pharmacoeconomics"', query time: 0.30s Refine Results
  1. 501
  2. 502

    Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. by Cassidy, J, Douillard, J, Twelves, C, McKendrick, J, Scheithauer, W, Bustová, I, Johnston, P, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K, Cowell, W, Garrison, L

    Published 2006
    “…Cost savings and better outcomes make capecitabine a preferred adjuvant therapy for Dukes' C colon cancer. This pharmacoeconomic analysis strongly supports replacing 5-FU/LV with capecitabine in the adjuvant treatment of colon cancer in the UK.…”
    Journal article
  3. 503
  4. 504
  5. 505
  6. 506
  7. 507
  8. 508
  9. 509
  10. 510
  11. 511
  12. 512
  13. 513
  14. 514
  15. 515
  16. 516
  17. 517
  18. 518
  19. 519
  20. 520